BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants. 2021

Yang Liu, and Jianying Liu, and Hongjie Xia, and Xianwen Zhang, and Jing Zou, and Camila R Fontes-Garfias, and Scott C Weaver, and Kena A Swanson, and Hui Cai, and Ritu Sarkar, and Wei Chen, and Mark Cutler, and David Cooper, and Alexander Muik, and Ugur Sahin, and Kathrin U Jansen, and Xuping Xie, and Philip R Dormitzer, and Pei-Yong Shi
University of Texas Medical Branch, Galveston, TX.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000071497 Immunogenicity, Vaccine The capacity of VACCINES to stimulate the ADAPTIVE IMMUNE RESPONSE to produce antibodies and antigen-specific T-CELL responses. It is typically measured in vaccinated individuals in observational studies setting. Antigenicity, Vaccine,Vaccine Antigenicity,Vaccine Immunogenicity
D000086382 COVID-19 A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent. 2019 Novel Coronavirus Disease,2019 Novel Coronavirus Infection,2019-nCoV Disease,2019-nCoV Infection,COVID-19 Pandemic,COVID-19 Pandemics,COVID-19 Virus Disease,COVID-19 Virus Infection,Coronavirus Disease 2019,Coronavirus Disease-19,SARS Coronavirus 2 Infection,SARS-CoV-2 Infection,Severe Acute Respiratory Syndrome Coronavirus 2 Infection,COVID19,2019 nCoV Disease,2019 nCoV Infection,2019-nCoV Diseases,2019-nCoV Infections,COVID 19,COVID 19 Pandemic,COVID 19 Virus Disease,COVID 19 Virus Infection,COVID-19 Virus Diseases,COVID-19 Virus Infections,Coronavirus Disease 19,Disease 2019, Coronavirus,Disease, 2019-nCoV,Disease, COVID-19 Virus,Infection, 2019-nCoV,Infection, COVID-19 Virus,Infection, SARS-CoV-2,Pandemic, COVID-19,SARS CoV 2 Infection,SARS-CoV-2 Infections,Virus Disease, COVID-19,Virus Infection, COVID-19
D000086402 SARS-CoV-2 A species of BETACORONAVIRUS causing atypical respiratory disease (COVID-19) in humans. The organism was first identified in 2019 in Wuhan, China. The natural host is the Chinese intermediate horseshoe bat, RHINOLOPHUS affinis. 2019 Novel Coronavirus,COVID-19 Virus,COVID19 Virus,Coronavirus Disease 2019 Virus,SARS Coronavirus 2,SARS-CoV-2 Virus,Severe Acute Respiratory Syndrome Coronavirus 2,Wuhan Coronavirus,Wuhan Seafood Market Pneumonia Virus,2019-nCoV,2019 Novel Coronaviruses,COVID 19 Virus,COVID-19 Viruses,COVID19 Viruses,Coronavirus 2, SARS,Coronavirus, 2019 Novel,Coronavirus, Wuhan,Novel Coronavirus, 2019,SARS CoV 2 Virus,SARS-CoV-2 Viruses,Virus, COVID-19,Virus, COVID19,Virus, SARS-CoV-2,Viruses, COVID19
D000086663 COVID-19 Vaccines Vaccines or candidate vaccines containing SARS-CoV-2 component antigens, genetic materials, or inactivated SARS-CoV-2 virus, and designed to prevent COVID-19. 2019 Novel Coronavirus Vaccine,2019 Novel Coronavirus Vaccines,2019-nCoV Vaccine,2019-nCoV Vaccines,COVID 19 Vaccine,COVID-19 Vaccine,COVID-19 Virus Vaccine,COVID-19 Virus Vaccines,COVID19 Vaccine,COVID19 Vaccines,COVID19 Virus Vaccine,COVID19 Virus Vaccines,Coronavirus Disease 2019 Vaccine,Coronavirus Disease 2019 Vaccines,Coronavirus Disease 2019 Virus Vaccine,Coronavirus Disease 2019 Virus Vaccines,Coronavirus Disease-19 Vaccine,Coronavirus Disease-19 Vaccines,SARS Coronavirus 2 Vaccines,SARS-CoV-2 Vaccine,SARS-CoV-2 Vaccines,SARS2 Vaccine,SARS2 Vaccines,2019 nCoV Vaccine,2019 nCoV Vaccines,COVID 19 Vaccines,COVID 19 Virus Vaccine,COVID 19 Virus Vaccines,Coronavirus Disease 19 Vaccine,Coronavirus Disease 19 Vaccines,SARS CoV 2 Vaccine,SARS CoV 2 Vaccines,Vaccine, 2019-nCoV,Vaccine, COVID 19,Vaccine, COVID-19,Vaccine, COVID-19 Virus,Vaccine, COVID19,Vaccine, COVID19 Virus,Vaccine, Coronavirus Disease-19,Vaccine, SARS-CoV-2,Vaccine, SARS2,Vaccines, 2019-nCoV,Vaccines, COVID-19,Vaccines, COVID-19 Virus,Vaccines, COVID19,Vaccines, COVID19 Virus,Vaccines, Coronavirus Disease-19,Vaccines, SARS-CoV-2,Vaccines, SARS2,Virus Vaccine, COVID-19,Virus Vaccine, COVID19,Virus Vaccines, COVID-19,Virus Vaccines, COVID19
D000090982 BNT162 Vaccine mRNA vaccine against SARS-CoV-2 developed by Pfizer and BioNTech. Abdavomeran,BNT-162A1,BNT-162B1,BNT-162B2,BNT-162C2,BNT162A1,BNT162B1,BNT162B2,BNT162C2,COVID-19 Vaccine Pfizer-BioNTech,Comirnaty,Pfizer Covid-19 Vaccine,Pidacmeran,Tozinameran,BNT 162A1,BNT 162B1,BNT 162B2,BNT 162C2,COVID 19 Vaccine Pfizer BioNTech,Covid-19 Vaccine, Pfizer,Pfizer Covid 19 Vaccine,Pfizer-BioNTech, COVID-19 Vaccine,Vaccine Pfizer-BioNTech, COVID-19,Vaccine, BNT162,Vaccine, Pfizer Covid-19
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies
D057134 Antibodies, Neutralizing Antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent, usually a virus. Neutralizing Antibodies,Antibody, Neutralizing,Neutralizing Antibody

Related Publications

Yang Liu, and Jianying Liu, and Hongjie Xia, and Xianwen Zhang, and Jing Zou, and Camila R Fontes-Garfias, and Scott C Weaver, and Kena A Swanson, and Hui Cai, and Ritu Sarkar, and Wei Chen, and Mark Cutler, and David Cooper, and Alexander Muik, and Ugur Sahin, and Kathrin U Jansen, and Xuping Xie, and Philip R Dormitzer, and Pei-Yong Shi
February 2022, Vaccines,
Yang Liu, and Jianying Liu, and Hongjie Xia, and Xianwen Zhang, and Jing Zou, and Camila R Fontes-Garfias, and Scott C Weaver, and Kena A Swanson, and Hui Cai, and Ritu Sarkar, and Wei Chen, and Mark Cutler, and David Cooper, and Alexander Muik, and Ugur Sahin, and Kathrin U Jansen, and Xuping Xie, and Philip R Dormitzer, and Pei-Yong Shi
June 2022, Small (Weinheim an der Bergstrasse, Germany),
Yang Liu, and Jianying Liu, and Hongjie Xia, and Xianwen Zhang, and Jing Zou, and Camila R Fontes-Garfias, and Scott C Weaver, and Kena A Swanson, and Hui Cai, and Ritu Sarkar, and Wei Chen, and Mark Cutler, and David Cooper, and Alexander Muik, and Ugur Sahin, and Kathrin U Jansen, and Xuping Xie, and Philip R Dormitzer, and Pei-Yong Shi
January 2021, Research square,
Yang Liu, and Jianying Liu, and Hongjie Xia, and Xianwen Zhang, and Jing Zou, and Camila R Fontes-Garfias, and Scott C Weaver, and Kena A Swanson, and Hui Cai, and Ritu Sarkar, and Wei Chen, and Mark Cutler, and David Cooper, and Alexander Muik, and Ugur Sahin, and Kathrin U Jansen, and Xuping Xie, and Philip R Dormitzer, and Pei-Yong Shi
January 2021, bioRxiv : the preprint server for biology,
Yang Liu, and Jianying Liu, and Hongjie Xia, and Xianwen Zhang, and Jing Zou, and Camila R Fontes-Garfias, and Scott C Weaver, and Kena A Swanson, and Hui Cai, and Ritu Sarkar, and Wei Chen, and Mark Cutler, and David Cooper, and Alexander Muik, and Ugur Sahin, and Kathrin U Jansen, and Xuping Xie, and Philip R Dormitzer, and Pei-Yong Shi
May 2022, Cell & bioscience,
Yang Liu, and Jianying Liu, and Hongjie Xia, and Xianwen Zhang, and Jing Zou, and Camila R Fontes-Garfias, and Scott C Weaver, and Kena A Swanson, and Hui Cai, and Ritu Sarkar, and Wei Chen, and Mark Cutler, and David Cooper, and Alexander Muik, and Ugur Sahin, and Kathrin U Jansen, and Xuping Xie, and Philip R Dormitzer, and Pei-Yong Shi
March 2021, NPJ vaccines,
Yang Liu, and Jianying Liu, and Hongjie Xia, and Xianwen Zhang, and Jing Zou, and Camila R Fontes-Garfias, and Scott C Weaver, and Kena A Swanson, and Hui Cai, and Ritu Sarkar, and Wei Chen, and Mark Cutler, and David Cooper, and Alexander Muik, and Ugur Sahin, and Kathrin U Jansen, and Xuping Xie, and Philip R Dormitzer, and Pei-Yong Shi
February 2022, Science (New York, N.Y.),
Yang Liu, and Jianying Liu, and Hongjie Xia, and Xianwen Zhang, and Jing Zou, and Camila R Fontes-Garfias, and Scott C Weaver, and Kena A Swanson, and Hui Cai, and Ritu Sarkar, and Wei Chen, and Mark Cutler, and David Cooper, and Alexander Muik, and Ugur Sahin, and Kathrin U Jansen, and Xuping Xie, and Philip R Dormitzer, and Pei-Yong Shi
August 2021, Nature communications,
Yang Liu, and Jianying Liu, and Hongjie Xia, and Xianwen Zhang, and Jing Zou, and Camila R Fontes-Garfias, and Scott C Weaver, and Kena A Swanson, and Hui Cai, and Ritu Sarkar, and Wei Chen, and Mark Cutler, and David Cooper, and Alexander Muik, and Ugur Sahin, and Kathrin U Jansen, and Xuping Xie, and Philip R Dormitzer, and Pei-Yong Shi
October 2021, Viruses,
Yang Liu, and Jianying Liu, and Hongjie Xia, and Xianwen Zhang, and Jing Zou, and Camila R Fontes-Garfias, and Scott C Weaver, and Kena A Swanson, and Hui Cai, and Ritu Sarkar, and Wei Chen, and Mark Cutler, and David Cooper, and Alexander Muik, and Ugur Sahin, and Kathrin U Jansen, and Xuping Xie, and Philip R Dormitzer, and Pei-Yong Shi
March 2022, Nature communications,
Copied contents to your clipboard!